TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Luteal Phase Support During Frozen Embryo Transfer Cycle

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with surplus embryos undergone infertility treatment cycles (e.g. OHSS, inadequate endometrium, surplus frozen embryo from any cause)~2. Age 21-37 years~3. Normal BMI (18.5 \<BMI \<30)~4. IVF / ICSI or IVF or ICSI cycles with antagonists or agonists protocols~5. Frozen embryos on 2-3 days~Exclusion Criteria:~1. Endometrial thickness ≤7mm~2. Egg Donors~3. Surrogacy~4. Male factor infertility with azoospermia~5. Age \<37 years old~6. Hydrosalpinx~7. Uterine anomalies~8. Myoma with a compression effect or submocusa myoma~9. PGD~10. Blastocyst embryo transfer, ZIFT and GIFT

- Gender: FEMALE
- Minimum Age: 21 Years
- Maximum Age: 37 Years
- Healthy Volunteers: t

Study Arms:
- FET cycle, discontinue estradiol after 6 gestational weeks (Type: EXPERIMENTAL): In patients 35 days after embryo transfer and observation of gestational sac with heart beat (6 weeks of pregnancy) by ultrasound, exogenous estrogen will discontinued while progesterone will remain daily use until twelfth week of pregnancy.
- FET cycle, continue estradiol till 12 gestational weeks (Type: ACTIVE_COMPARATOR): Control group receive 6 mg oral estrogen and 100 mg intramuscularly progesterone until 12 week of pregnancy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Antenatal Corticosteroids on Neonatal Morbidity.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Pregnant women at 34 weeks 0 days to 36 weeks 6 days of gestation and a probability of delivery in the late preterm period irrespective of diagnosis who give consent.~* Pregnant women at 34 weeks 0 days to 36 weeks 6 days of gestation scheduled for elective/emergency delivery in the late preterm period irrespective of indication and route of delivery who give consent.~Exclusion Criteria:~* Evidence of Chrioamnionitis.~* Evidence of foetal distress.~* History of use of antenatal corticosteroids in index pregnancy.~* Women who do not give consent.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 49 Years
- Healthy Volunteers: t

Study Arms:
- Dexamethasone sodium phosphate injection (Type: EXPERIMENTAL): Intervention: Drug: Dexamethasone sodium phosphate injection Two doses Intramuscular Dexamethasone sodium phosphate 12mg given12 hours apart. (produced by Taizhou Overseas International Ltd. 126-128 Qingnian Road Jiaojiang, Taizhou, Zhejiang, China)
- Betamethasone sodium phosphate injection (Type: EXPERIMENTAL): Intervention: Drug: Betamethasone sodium phosphate injection Two doses of intramuscular betamethasone sodium phosphate 12mg given 12 hours apart. (obtained from Twinbrook pkwy, Rockville, MD Singapore. CAT No 1068004, Lot: R004e0)
- Water for injection (Type: PLACEBO_COMPARATOR): Intervention. Drug: Water for injection. Two doses of intramuscular water for injection given 12 hours apart.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Home Safety Clinical Trial for Alzheimer's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects are dyads of primary caregivers and persons with a progressive DAT who live in the community, are willing to have home visits for home safety education, and who read and speak English.~* Inclusion criteria for care recipients are: diagnosis of DAT, score of 24 or less on the Mini-Mental State Exam (MMSE), is expected to continue living in the community for the next 6 months, and has the ability to ambulate without help from the caregiver.~* Inclusion criteria for the primary informal caregiver are: lives in the home with the care-recipient, provides a minimum of 4 hours of care-giving or supervision per day, and has no known cognitive impairment as judged by the primary care provider who refers the subject dyad for study recruitment.~Exclusion Criteria:~* Care-recipient MMSE score of 25 or greater.~* A previous home safety visit.~* Admission to a long-term care facility. - Persons with DAT who are living alone will be excluded because their safety issues are more complex and there is no primary informal caregiver who can make consistent observations about risky behaviors and accidents.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Home Safety Toolkit (Type: EXPERIMENTAL): Intervention group receives home safety tool-kit with education and self-efficacy materials to promote competence to make home safety modifications.
- Conventional Safety Checklist (Type: NO_INTERVENTION): Comparison group received a conventional home safety checklist

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Enteral Nutrition in the Treatment of Pancreatic Fistulas - A Prospective Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* the presence of pancreatic fistula (PF) (verification of serum lipase concentration in drained fluid, findings on imaging modalities: endoscopic retrograde cholangiopancreatography (ERCP), helical computed tomography(hCT), magnetic reissonance imaging (MRI), ultrasonography (USG) or intraoperative surgeon's verification - any or some or all of them)~* good general status (Karnoffsky \> 80, Eastern Cooperative Oncology Group (ECOG) scale 0 or 1; see Appendix 2);~* NRS and MUST evaluation - low/ medium risk patients not requiring parenteral nutrition as the essence treatment option,~* no PF's complication requiring special treatment present, such as intraabdominal abscess formation, pleuropneumonia, bleeding, paralytic ileus, etc. Complications will be diagnosed and treated according to generally accepted medical knowledge, standards and procedures.~* age below 80 and over 18;~* in case of neoplastic patients: no confirmed neoplastic dissemination nor distant metastases;~* no severe concomitant disease (heart failure, COPD, CABG, etc.);~* no history of known allergies or drug intolerance;~* informed consent~Exclusion Criteria:~* PF diagnosis uncertain;~* poor general status (Karnoffsky \<80, ECOG \> 1);~* the presence of serious complications; see above~* recent history of severe heart, lung, kidney or liver failure;~* the history of allergies or drug intolerance;~* confirmed neoplastic spread;~* severe malnutrition requiring combined treatment (PN+EN)~* withdrawal of consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Food Effect Study For Apixaban Commercial Image Tablets

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy volunteers~Exclusion Criteria:~* History or evidence of abnormal bleeding or coagulation disorder (eg, easy bruising or gingival bleeding, prolonged bleeding after dental extraction, postpartum, or after trauma, wounds or surgery) and/or having a first degree relative under 50 years of age with a history of abnormal bleeding or coagulation disorder

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): Period I: fasting state, Period II: fed state
- 2 (Type: EXPERIMENTAL): Period I: fed state, Period II: fasting state

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of TRD~Exclusion Criteria:~* Other comorbidities

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Low dose (Type: EXPERIMENTAL): Low dose Psilocybin
- Medium dose (Type: EXPERIMENTAL): Medium dose Psilocybin
- High dose (Type: EXPERIMENTAL): High dose Psilocybin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Tumor-Infiltrating Lymphocytes And Low-Dose Interleukin-2 Therapy Following Cyclophosphamide And Fludarabine In Patients With Melanoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria (Eligibility for TIL Evaluation):~* Must have measurable, unresectable stage III or stage IV melanoma~* Suitable tumor for collection~* If tumor is suitable for collection, patient must be suitable for surgery~* Patient must be 18 years of age or older~* Performance status of ECOG 0 or 1~* Life expectancy \> 5 months from date of consent of TIL evaluation~* Willing to be tested for transmissible diseases~* For patients with a history of allergy to penicillin, gentamycin, streptomycin, or anti-fungals, the ability to generate TILs will be confirmed with the cell manufacturing laboratory~Inclusion Criteria (Eligibility for Treatment):~* Signed and dated the informed consent~* No brain metastases or stable brain metastases for 3 months following definitive treatment.~* Life expectancy \> 3 months from the date of consent for TILs treatment~* TILs are suitable for use as determined by laboratory~* More than 30 days since any prior systemic therapy at the time of the cell infusion, or more than six weeks since prior nitrosurea therapy. For patients with prior ipilimumab therapy, at least six weeks must elapse between the last ipilimumab dose and the start of study treatment. All side effects from previous treatment must have recovered to an acceptable grade level.~* Adequate organ function~* Must have positive EBV titres~* Women of child-bearing potential must have a negative pregnancy test. Patients of both genders must be willing to practice birth control during treatment and for 6 months post completion of IL-2 treatment.~Exclusion Criteria:~* Requiring systemic steroid therapy~* HIV positive~* With active hepatitis B or hepatitis C, syphilis, or HTLV~* Must not have any active systemic infections, coagulation disorders or other active major medical illnesses of the cardiovascular, respiratory or immune system, uncontrolled psychiatric disorders, or other conditions that may affect following study procedures.~* Have no active underlying cardiac illnesses defined by positive stress test, LVEF\<40% or ongoing life-threatening arrhythmias~* Abnormal lung function test

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cyclophosphamide and Fludarabine followed by TILs and IL-2 (Type: EXPERIMENTAL): Cyclophosphamide, i.v., 60mg/kg per day for 2 days and Fludarabine, i.v., 25mg/m2 per day for 5 days; then Tumor-Infiltrating Lymphocytes, i.v., 1x10\^10 - 1.6x10\^11 cells and Low-Dose Interleukin, i.v., 125,000 IU/kg subcut per day, for 2 weeks (2 days rest between each week)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparative Evaluation of Herbal and Allopathic Drugs for the Treatment of Chronic Diarrhea

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female adults between the age of 18-60 years who were suffering from diarrhea of presumed infectious origin and willing to participate were eligible for inclusion in the study.~Exclusion Criteria:~* Exclusion criteria were the presence of chronic~* Iatrogenic, or bloody diarrhea, having received antibiotic treatment for other medical or surgical problems~* Having a history of renal or hepatic dysfunction~* Having a concomitant infection.~* Patients receiving treatment with an anti-diarrheal drug in the five days prior to the study were also excluded.~* Pregnant or lactating women and women planning pregnancy were also ineligible for study participation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Entoban Capsules (Type: EXPERIMENTAL): Entoban is the combination of Holarrhena antidysenterica, Berberis aristata, Symplocos racemosa, Querecus infectoria and Helicteres isora.
- Metronidazole DS (Type: EXPERIMENTAL): Metronidazole DS(400 mg) is commonly used to treat diarrhea.It eliminates bacteria and other microorganisms that cause infections of the reproductive system, gastrointestinal tract, skin, vagina, and other areas of the body.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Ravidasvir in Combination With Danoprevir/r and Ribavirin(RBV) in Treatment-naive, Non-cirrhotic, Chronic Hepatitis C Virus Genotype1 Infected Subjects.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Infection with Chronic hepatitis C genotype 1confirmed at screening;~* Anti-HCV positive；~* HCV RNA ≥1 × 10000IU / mL;~* Not treated with interferon and / or any other direct-acting antiviral (DAA) drug;~* Non-cirrhotic;~* Voluntarily sign informed consent.~Exclusion Criteria:~* HCV genotypes 2 to 7 or undetectable HCV genotype or mixed HCV genotype;~* Fibroscan detection result \> 12.9kPa or Histopathological examination result of patients is with cirrhosis;~* Past or existing evidence of the presence of non-HCV-induced chronic liver disease;~* Previous history of hepatocellular carcinoma, or suspected hepatocellular carcinoma found prior to screening, or suspected abdominal hepatoblastoma at screening or AFP\>100ng/mL;~* Anti-HAV (IgM) 、HBsAg 、anti-HEV (IgM) or anti-HIV is positive;~* BMI\<18 or≥30 kg/m2;~* ANC\<1.5×109/L、PLT\<100×109/L、HB\<110g/L（female）or\<120g/L（male）；INR\>1.5；ALT or AST≥5\*ULN；TBIL≥2\*ULN（DBIL≥ 35%TBIL）；Cr≥1.5\*ULN;~* Others as specified in detailed protocol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Experimental Group (Type: EXPERIMENTAL): Ravidasvir + Danoprevir + Ritonavir + Ribavirin
- Placebo Group (Type: PLACEBO_COMPARATOR): Ravidasvir placebo + Danoprevir placebo + Ritonavir placebo + Ribavirin placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Stem Cell Transplantation to Treat Dilated Cardiomyopathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Normal coronary angiogram~* Left ventricular ejection fraction \< 40%~* NYHA III or IV heart failure symptoms~* Bone marrow reactivity (G-CSF test)~* Presence of viable myocardium~Exclusion Criteria:~* Hematologic malignancy~* Multiorgan failure

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- SC Group (Type: EXPERIMENTAL): SC therapy,'Bone Marrow Stimulation','CD34+ autologous stem cell transplantation':~In the SC group, CD34+ cells were mobilized by granulocyte colony-stimulating factor and collected via apheresis. Patients underwent myocardial scintigraphy and cells were injected in the artery supplying segments with the greatest perfusion defect
- Controls (Type: NO_INTERVENTION): Patients receiving no cell therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Using Nevirapine to Prevent Mother-to-Child HIV Transmission During Breastfeeding

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Note: As of 08/10/07, the arm assignments for current and new participants have changed. Please see the above description for this trial for more information.~Inclusion Criteria for Mothers:~* 18 years of age or older~* HIV infected~* In third trimester of pregnancy, or at most 3 days post-delivery~* If baby is not yet born, planning to deliver at a facility where the study is being conducted~* Plan to breastfeed~Exclusion Criteria for Mothers:~* Complications with this pregnancy~* Serious medical condition that would interfere with the study (e.g., that would prevent breastfeeding or adherence to the follow-up schedule), as judged by the on-site clinician~Inclusion Criteria for Infants:~* Born to an HIV infected mother who is eligible for the study~* Weighed at least 2000 grams (4.4 lbs) at birth~* Blood sample obtained from the infant for HIV-1 DNA PCR, CBC with differential, and ALT~* Infants in a multiple birth are eligible only if both/all infants are eligible for the study and assigned to the same study group~* Able to breastfeed (e.g., mother and infant alive with no condition apparent that would prevent breastfeeding)~Exclusion Criteria for Infants:~* HIV DNA PCR positive at birth~* ALT of Grade 2 or higher at birth~* Hemoglobin, absolute neutrophil count, or platelet count of Grade 3 or higher at birth~* Skin rash of Grade 2B (urticaria), Grade 3, or above~* Confirmed or suspected clinical hepatitis~* Serious illness or condition that would interfere with compliance with study procedures

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 2A (Type: EXPERIMENTAL): For infants: extended treatment with NVP
- 2B (Type: PLACEBO_COMPARATOR): For infants: extended treatment with NVP placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effects of Pentoxifylline on PAI-1 in an Obese Population

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusions: 1. A Body Mass Index of ≥ 30.0 2. Age 21 or older 3. Few or no medical problems 4. PAI-1 level ≥ 10 ng/dl~Exclusions: 1. Cigarette use 2. Present use of angiotensin converting enzyme (ACE) Inhibitors 3. Recent cerebral and/or retinal hemorrhage 4. Intolerance to pentoxifylline or methylxanthines such as caffeine, theophylline, and theobromine 5. Presently on warfarin therapy 6. Pregnancy or breast-feeding 7. Recent surgery 8. Recent diagnosis/treatment for peptic ulcer

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Pentoxifylline (Type: EXPERIMENTAL): Patients receive Pentoxifylline 400 mg po TID for 8 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Patients take a placebo TID for 8 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: In Vivo and in Vitro Efficacy of Antimalarial Treatments in Children in Burkina Faso

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 6 - 59 months~* Weight \> 5 kg~* Mono-infection with P. falciparum~* Parasitemia of 4,000-200,000 asexual parasites per µl~* Fever: \> 37.5 °C or history of fever in the preceding 24 hours~* Haemoglobin \> 5.0 g/dl~* Signed informed consent by the parents or guardians~* Parents' or guardians' willingness and ability to comply with the study protocol for the duration of the trial.~Exclusion Criteria:~* Participation in any other clinical trial during the previous 30 days~* Known hypersensitivity to the study drugs~* Severe and/or complicated malaria (cases will be referred to Bobo-Dioulasso University hospital for treatment)~* Danger signs: not able to drink or breast-feed, vomiting (\> twice in 24hours), recent history of convulsions (\>1 in 24h), unconscious state, unable to sit or stand;~* Known intercurrent illness or any condition which would place the subject at undue risk or interfere with the results of the study.~* Severe malnutrition (weight for height \<70% of the median NCHS/WHO reference)

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 15 Years
- Healthy Volunteers: f

Study Arms:
- Artemether -lumefantrine (Type: EXPERIMENTAL): Treatment of malaria with Artemether-lumefantrine (AL), according to one of the two options given by national protocol in Burkina Faso
- Artesunate-amodiaquine (Type: EXPERIMENTAL): Treatment of malaria with Artesunate-amodiaquine(AS-AQ), according to one of the two options given by national protocol in Burkina Faso

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete